The Evidence Based Rheumatology Podcast cover art

All Episodes

The Evidence Based Rheumatology Podcast — 101 episodes

#
Title
1

E135: IL17 and a GLP1?

2

E134: Brepocitinib in Dermatomyositis (VALOR)

3

E133: Obinutuzumab for SLE (ALLEGORY)

4

E132: Romosozumab vs teriparatide for osteoproosis (STRUCTURE)

5

E131: A Sham-Controlled Sham of a Trial: RESET-RA

6

E130: Telitacicept for SLE

7

E129: Long Term Routine Laboratory Monitoring in RA

8

E128: Nerandomilast for Autoimmune ILD (FIBRONEER-ILD)

9

E127: TNFs and All That CHF

10

E126: Risk Signals, JAKs, and SELECTIVE-ity

11

E125: Adrenal Insufficiency after Stopping Prednisone

12

e124: MTX vs Pred for Pulmonary Sarcoidosis: PREDMETH Study

13

E123: Upadacitinib for Giant Cell Arteritis: SELECT-GCA

14

E122: Guidelines for Maybe Diagnosing HLH

15

E121: Obinutuzumab in SLE-LN

16

E120: Real Life Use of PEXIVAS-Low

17

E119: Teclistamab for Rheumatology Writ Large

18

E118: The emerging risk of overdiagnosis in RA and PMR

19

E117: Inebilizumab for IgG4-RD (MITIGATE)

20

E116: A New Paradigm for PMR

21

E115: Benralizumab for EGPA - the MANDARA Study

22

E114: Target Trials and STAR-RA with Rishi Desai

23

E113: CAR-T is Coming to Rheumatology

24

E112: Gabapentin is Trash

25

E111: PEXIVAS Subsets with Mike Walsh & Mats Junek

26

E110: Rheum4Debate - Screening for RA-ILD with Joshua Solomon and Scott Matson

27

E109: Abatacept for Pre-RA - the ARIAA Study

28

E108: Myositis Guidelines for Cancer Screening w/Alexander Oldroyd

29

E107: Fragility of SLE Randomized Controlled Trials

30

E106: GCA/PMR with Bhaskar Dasgupta

31

E105: Autoimmunity Post COVID-19?

32

E104: Sarilumab for PMR - The SAPHYR Study

33

E103: Len Calabrese on Monoclonal Antibodies for COVID-19

34

E102: Unintentional Unblinding in Rheumatic Disease Trials

35

E101: Pred v Colchicine for CPPD: COLCHICORT

36

E100: ADVOCATE Health Related Quality of Life

37

E99: Hospital Problems

38

E98: Key Opinion Leaders & ILD Guidelines

39

E97: Does allopurinol reduce CVD? The ALLHEART Study

40

E96: Long COVID - Where to After Norway?

41

E95: Rituximab or Cyclophosphamide in ANCA Vasculitis

42

E94: Steroids and Psoriasis Flares

43

E93: Azathioprine is the Worst

44

E92: Are muscle symptoms from statins imaginary?

45

E91: Clinical Innovation in Rheumatology: Past, Present, and Future

46

E90: There Is No Diagnosis of Exclusion in Rheumatology

47

E89: Vitamin D to Prevent Osteoporotic Fractures

48

E88: HCQ Dose Reductions and SLE Flares

49

E87: IVIG for Dermatomyositis

50

E86: Target Trials and Causality in Rheumatology

51

E85: Challenging Wisely

52

E84: The JAKapocalypse (AKA ORAL Surveillance)

53

E83: Effectiveness of COVID-19 Vaccines

54

E82: LoVAS Trial for ANCA Vasculitis

55

E81: Vasculitis Guidelines E7: Takayasu Arteritis with Dr. Andy Abril

56

E80: Vasculitis Guidelines E6 - Polyarteritis Nodosa with Dr. Jason Springer

57

E79: Vasculitis Guidelines E5 - GCA with Dr. Mehrdad Maz

58

E78: Vasculitis Guidelines #4 - EGPA with Dr. Phil Seo

59

E77: Vasculitis Guidelines #3 - ANCA Vasculitis with Dr. Sharon Chung

60

E76: Voclosporin for SLE Nephritis: The AURORA RCT

61

E75: Vasculitis Guidelines Episode 2: Overview with Sharon Chung

62

E74: Vasculitis Guidelines Episode 1 - Joyce Kullman

63

E73: Introducing the Vasculitis Guidelines Podcast

64

E72: Avacopan for ANCA Vasculitis

65

E71: MTX Discontinuation Post... Influenza Vaccination

66

E70: Rheum4Debate - HCQ Levels Should Be Monitored in Patients with SLE

67

E69: Publication Trends in SRMAs and RCTs

68

E68: SELECT-CHOICE Upadacitinib vs Abatacept in RA

69

E67: Belimumab in Lupus Nephritis (BLISS-LN)

70

E66: MRI to Diagnose PMR

71

E65: Anifrolumab in SLE - A Reply

72

E63: Housekeeping #3

73

E57: PEXIVAS Trial - PLEX and Reduced Steroid in ANCA Vasculitis

74

E56: Continue or Withdraw Prednisone in SLE (CORTICOLUP)

75

E55: Anifrolumab for SLE (TULIP 1&2)

76

E54: Rheum4Debate - Triple Tx is 1st Line in RA w/No Response to MTX

77

E53: Another Look at Nintedanib for SSc-ILD

78

E52: HOPE RCT - Prednisone for OA of the Hand

79

E51: Rheum4Debate - "Start TCZ Upfront in GCA"

80

E50: Housekeeping 2

81

E49: IL17i vs. TNFi for Psoriatic Arthritis (SPIRIT-H2H)

82

E48: ADACTA - Tocilizumab or Adalimumab in MTX Intolerant Patients with RA

83

E47: HCQ Blood Levels and HCQ Retinopathy

84

E46: Rituximab in Lupus

85

E45: TNF or TCZ or ABA or RTX: Real World Data for RA

86

E44: SELECT-COMPARE Upadacitinib (JAKi) for Rheumatoid Arthritis

87

E43: Tofacitinib for MDA5 Amyopathic Dermatomyositis ILD

88

E42: SENSCIS - Nintedanib for Systemic Sclerosis ILD

89

E41: Rheum4Debate "SLE Pts. on Cytoxan Should Receive Bactrim"

90

E40: Rheum4Debate - "SCT is 1st Line Tx for SSc ILD"

91

E39: MTX for GCA - 3 RCTs and a Case Control Study

92

E38: Romosozumab for Osteoporosis

93

E37: TRACE-RA Atorvastatin for Primary Prevention of CVD in RA

94

E36: Baricitinib for SLE

95

E35: Tramadol Associated with All Cause Mortality

96

E34: Leggo my Eggo! Eggs, Cholesterol, CVD, Mortality

97

E33: FDG-PET for GCA

98

E32: TaSER and ARCTIC: U/S to Guide Treatment in Inflammatory Arthritis

99

E31: SEAM and MIPA Trials: MTX vs. ETN for Psoriatic Arthritis

100

E30: The Quality of RCTs in the Rheum Literature

101

E29: CIRT and CANTOS - Immunotherapy for Cardiovascular Disease